712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors
Heather Metz, Ty Brender, Brenda Stevens, Damion Winship, Jamie Brevik, Michael Comeau, Monica Childs, Jenny Chang, Li-Qun Fan, Hengyu Xu, Jonathan Grey, Jeffrey Adamo, Ben Setter, Ray Carrillo, Sean Smith, Phil Tan, Robert DuBose, Yvette Latchman, Peter Baum, Valerie Odegard
Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A427; DOI: 10.1136/jitc-2020-SITC2020.0712